Shanghai OPM Biosciences Co., Ltd. (SHA:688293)

Market Cap	6.49B
Revenue (ttm)	352.91M
Net Income (ttm)	43.24M
Shares Out	113.82M
EPS (ttm)	0.37
PE Ratio	155.61
Forward PE	89.06
Dividend	0.42 (0.74%)
Ex-Dividend Date	Sep 15, 2025

Volume	707,434
Average Volume	1,377,977
Open	56.48
Previous Close	56.48
Day's Range	56.35 - 57.35
52-Week Range	31.85 - 67.80
Beta	0.74
RSI	60.10
Earnings Date	Apr 23, 2026

About Shanghai OPM Biosciences

Shanghai OPM Biosciences Co., Ltd. provides cell culture media and CDMO services in China and internationally. The company offers cell culture media and feed supplements, such as OPM's CHO-Platform, OPM-293 Platform, and VegaCHO media and feeds, as well as customized cell culture media development services. It also provides end-to-end biologics CDMO services, such as antibody discovery, stable cell line development, cell banking, upstream process development, downstream process development, formulation development, and quality control and produ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 328
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688293

Financial Performance

In 2024, Shanghai OPM Biosciences's revenue was 297.24 million, an increase of 22.26% compared to the previous year's 243.12 million. Earnings were 21.05 million, a decrease of -61.04%.